Home » News » India » Synairgen's Drug Shows Reduced Risk of Severe Disease in Covid-19 Patients
1-MIN READ

Synairgen's Drug Shows Reduced Risk of Severe Disease in Covid-19 Patients

Representative Image. (AP Photo/Jessica Hill, File)

Representative Image. (AP Photo/Jessica Hill, File)

The trial, which used interferon beta, showed that patients who were given Synairgen's formulation had a 79% lower risk of developing severe disease compared to placebo.

Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.

The trial, which used interferon beta, showed that patients who were given Synairgen's formulation had a 79% lower risk of developing severe disease compared to placebo.

Patients who received the drug, SNG001, were more than twice as likely to recover from COVID-19 as those on placebo, the company said.

Interferon beta is a naturally occurring protein, which regulates the body's antiviral responses.

first published:July 20, 2020, 13:35 IST